Literature DB >> 16405880

Incorporation of PEG-lipids in arsonoliposomes results in formation of highly stable arsenic-containing vesicles.

Sophia Piperoudi1, Dimitris Fatouros, Panayiotis V Ioannou, Peter Frederik, Sophia G Antimisiaris.   

Abstract

We investigated the effect of pegylation on the physical stability, morphology and membrane integrity of arsonoliposomes. Arsonoliposomes composed of distearoylglycerophosphocholine (DSPC), cholesterol (Chol) and the palmitoyl side chain arsonolipid (with concentrations ranging from 0 mol% [DSPC/Chol vesicles] to 53 mol% of total lipid) containing either 4 or 8 mol% DPPE-PEG2000 or DSPE-PEG2000, were prepared by sonication. Arsonoliposome membrane integrity was evaluated by measuring the retention of encapsulated calcein in vesicles (during incubation in buffer or fetal calf serum [FCS]) while physical stability was evaluated by measuring vesicle dispersion turbidity (during incubation in water or CaCl(2)). Vesicle morphology was studied by cryo-electron microscopy. Experimental results show that: (i) PEG-lipids are incorporated in arsonoliposomes (as confirmed by the vesicle zeta potential modulation), (ii) pegylation of arsonoliposomes prevents their aggregation and fusion in the presence of calcium ions and (iii) when 8 mol% of PEG-DSPE is incorporated in arsonoliposomes based on their arsonolipid content, two groups of pegylated vesicles are formed: low content arsonoliposomes (<20 mol% arsonolipid) which are highly leaky and high content arsonoliposomes (>27 mol% arsonolipid) which are highly stable (70% calcein retention after 24h incubation in fetal calf serum [FCS]). In addition to high membrane integrity, the high content pegylated arsonoliposomes are morphologically perfect round-shaped vesicles without the sharp edges typically observed with non-pegylated DSPC-containing arsonoliposomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16405880     DOI: 10.1016/j.chemphyslip.2005.11.003

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  6 in total

1.  Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure.

Authors:  John D Hoekman; Pramod Srivastava; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2014-06-06       Impact factor: 3.534

2.  The bifunctional liposomes constructed by poly(2-ethyl-oxazoline)-cholesteryl methyl carbonate: an effectual approach to enhance liposomal circulation time, pH-sensitivity and endosomal escape.

Authors:  Huan Xu; Wei Zhang; Yan Li; Fei F Ye; Peng P Yin; Xiu Yu; Mei N Hu; Yuan S Fu; Che Wang; De J Shang
Journal:  Pharm Res       Date:  2014-05-08       Impact factor: 4.200

3.  Moxifloxacin Liposomes: Effect of Liposome Preparation Method on Physicochemical Properties and Antimicrobial Activity against Staphylococcus epidermidis.

Authors:  Evangelos Natsaridis; Foteini Gkartziou; Spyridon Mourtas; Marc C A Stuart; Fevronia Kolonitsiou; Pavlos Klepetsanis; Iris Spiliopoulou; Sophia G Antimisiaris
Journal:  Pharmaceutics       Date:  2022-02-07       Impact factor: 6.321

4.  Synthesis of Novel Arsonolipids and Development of Novel Arsonoliposome Types.

Authors:  Spyridon Mourtas; Konstantina Papadia; Golfo G Kordopati; Panayiotis V Ioannou; Sophia G Antimisiaris; Gerasimos M Tsivgoulis
Journal:  Pharmaceutics       Date:  2022-08-08       Impact factor: 6.525

5.  Preparation, Physicochemical Properties, and In Vitro Toxicity towards Cancer Cells of Novel Types of Arsonoliposomes.

Authors:  Paraskevi Zagana; Spyridon Mourtas; Anastasia Basta; Sophia G Antimisiaris
Journal:  Pharmaceutics       Date:  2020-04-06       Impact factor: 6.321

6.  Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats.

Authors:  Minghan Shi; Malathi Anantha; Mohamed Wehbe; Marcel B Bally; David Fortin; Laurent-Olivier Roy; Gabriel Charest; Maxime Richer; Benoit Paquette; Léon Sanche
Journal:  J Nanobiotechnology       Date:  2018-10-05       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.